Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Neoplasms of the CNS

Free Subscription Articles published in J Neuropathol Exp Neurol Retrieve available abstracts of 93 articles: HTML format

Single Articles

December 2025
1. FUKUOKA K, Irikura T, Kanemura Y, Hirato J, et al
   Intratumoral heterogeneity of MYC status and methylation subtyping in group 3 medulloblastoma: A case report.
   J Neuropathol Exp Neurol. 2025 Dec 23:nlaf153. doi: 10.1093.
   PubMed    
   
   
   
2. MAFFICINI A, Pigato F, Miele E, Patrizi S, et al
   Fumarate hydratase-mutant glioma with giant-cell histology, MSH6 mutation, and hypermutation.
   J Neuropathol Exp Neurol. 2025 Dec 9:nlaf142. doi: 10.1093.
   PubMed    
   
   
   
3. CHIANG WY, Li X, Tanaka R, Chiang J, et al
   Activated signaling pathways and metabolic processes in disseminating myxoid glioneuronal tumors.
   J Neuropathol Exp Neurol. 2025;84:1106-1112.
   PubMed     Abstract available
   
   
   November 2025
4. BELAKHOUA S, Lopez G, Dubey S, Rai S, et al
   RECQL4 alterations in gliomas and nerve sheath tumors: Expression patterns and therapeutic implications.
   J Neuropathol Exp Neurol. 2025 Nov 29:nlaf129. doi: 10.1093.
   PubMed     Abstract available
   
   
   
5. BROECHNER A, Maier AD, Mirian C, Sahm F, et al
   Analysis of anatomical location, mitoses, and Ki-67 in 2608 meningiomas.
   J Neuropathol Exp Neurol. 2025 Nov 20:nlaf131. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. WELCH RL, Fluss RS, Yokoda RT, Himes BT, et al
   Primary sporadic intracranial DICER1 mutant sarcoma with SSTR2 positivity in an adult patient mimicking anaplastic meningioma.
   J Neuropathol Exp Neurol. 2025 Nov 11:nlaf053. doi: 10.1093.
   PubMed    
   
   
   
7. WENG M, Zhu X
   FOXM1/CENPI axis regulation of proline and arginine metabolism in glioblastoma cells.
   J Neuropathol Exp Neurol. 2025 Nov 4:nlaf121. doi: 10.1093.
   PubMed     Abstract available
   
   
   October 2025
8. MANDARA MT, Giglia G, Benedetti G, Falzone C, et al
   Tumor-associated macrophages in feline meningiomas: Exploring their prognostic significance.
   J Neuropathol Exp Neurol. 2025 Oct 21:nlaf119. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. MURAYI R, El-Abtah M, Ejikeme T, Xiao T, et al
   Validation of an immunohistochemistry-based molecular group stratification of intracranial meningiomas.
   J Neuropathol Exp Neurol. 2025 Oct 15:nlaf120. doi: 10.1093.
   PubMed     Abstract available
   
   
   September 2025
10. GUO Y, Liu H, Gao Z, Zhou Z, et al
    Mitochondrial dysfunction and its impact on pyroptosis and ferroptosis cross talk in glioma cells.
    J Neuropathol Exp Neurol. 2025 Sep 17:nlaf099. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. VOONG V, Beccari S, Hashemi E, Kriener B, et al
    3D spatial sampling to quantify morphologic heterogeneity in isocitrate dehydrogenase-wildtype glioblastoma.
    J Neuropathol Exp Neurol. 2025 Sep 3:nlaf101. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
12. ZHANG Z, Guo X, Qi T, Wang C, et al
    METTL14/IGF2BP2-mediated m6A modification of PD-L1 promotes proliferation, metastasis, and immune escape in high-grade gliomas.
    J Neuropathol Exp Neurol. 2025 Aug 11:nlaf090. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2025
13. HAO Z, Han Y, Bo Y, Cao L, et al
    Knocking down RFWD3 suppresses the growth and migration of glioblastoma cells by blocking G2/M cycle progression.
    J Neuropathol Exp Neurol. 2025 Jul 23:nlaf087. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. LIECHTY B, Kim S, Dobri G, Schwartz TH, et al
    SSTR2 expression in neoplastic and normal anterior pituitary is impacted by age, sex, and hormonal status.
    J Neuropathol Exp Neurol. 2025;84:626-633.
    PubMed     Abstract available
    
    
    
15. HARPER SD, Perryman T, Dudley LA, Prabhu AS, et al
    Molecular characterization of benign intracranial glioependymal and arachnoid cysts suggest heterogeneous mechanisms of action.
    J Neuropathol Exp Neurol. 2025;84:617-625.
    PubMed     Abstract available
    
    
    
16. SIDDIQ Z, Gilani A, Ung TH, Kleinschmidt-DeMasters BK, et al
    Isocitrate dehydrogenase-mutant astrocytoma in persons aged 55 years and older: Survival differences versus the young.
    J Neuropathol Exp Neurol. 2025;84:611-616.
    PubMed     Abstract available
    
    
    June 2025
17. LOCHNER RH, Powell SZ, Fung KM, Zhang YJ, et al
    FGFR1 fusions in genomically and epigenetically bona fide glioblastoma, IDH-wildtype.
    J Neuropathol Exp Neurol. 2025 Jun 12:nlaf068. doi: 10.1093.
    PubMed    
    
    
    
18. TERRY M, Reis G, Pekmezci M, Phillips JJ, et al
    PAS+/PASD- intracytoplasmic glycogen is not specific for clear cell meningioma.
    J Neuropathol Exp Neurol. 2025 Jun 6:nlaf065. doi: 10.1093.
    PubMed    
    
    
    May 2025
19. TOLLEFSEN SE, Meta R, Solheim O, Mjones P, et al
    Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas.
    J Neuropathol Exp Neurol. 2025 May 30:nlaf058. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. TAUZIEDE-ESPARIAT A, Rousseau A, Basset L, Saffroy R, et al
    A comparison of CDKN2A status in gliomas using different techniques: The loss of p16 as a surrogate marker.
    J Neuropathol Exp Neurol. 2025 May 30:nlaf062. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. FURUTA T, Miyoshi H, Moritsubo M, Nakajima R, et al
    Biological role and clinicopathological significance of leucine-rich alpha-2 glycoprotein 1 in the glioblastoma microenvironment.
    J Neuropathol Exp Neurol. 2025 May 9:nlaf049. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. ROBINS SM, Rosenblatt M, Bruce JN, Canoll P, et al
    Solitary fibrous tumor in the pineal region: A series of 5 cases and literature review.
    J Neuropathol Exp Neurol. 2025;84:379-390.
    PubMed     Abstract available
    
    
    April 2025
23. COOK DJ, Decker PA, Hardcastle JJ, Kollmeyer TM, et al
    EGFR transcript variants: Potential diagnostic biomarker for glioblastoma, IDH-wildtype?
    J Neuropathol Exp Neurol. 2025 Apr 25:nlaf041. doi: 10.1093.
    PubMed    
    
    
    
24. UGWUOWO U, Faust B, Tang H, DiStasio M, et al
    Adequate capture of spatial heterogeneity of Ki-67 proliferative index in meningiomas requires multiple tissue sections.
    J Neuropathol Exp Neurol. 2025 Apr 21:nlaf043. doi: 10.1093.
    PubMed    
    
    
    
25. DONO A, Pichardo-Rojas D, Mendoza Mora L, Pichardo-Rojas PS, et al
    MTAP immunohistochemistry as a surrogate marker of CDKN2A loss in brain tumors: A meta-analysis and literature review.
    J Neuropathol Exp Neurol. 2025 Apr 18:nlaf033. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. LI Y, Shen X, Zhang J, Xian X, et al
    Adult diffuse IDH-wildtype lower-grade gliomas with PDGFRA gain/amplification should be upgraded as glioblastoma.
    J Neuropathol Exp Neurol. 2025 Apr 16:nlaf039. doi: 10.1093.
    PubMed     Abstract available
    
    
    
27. NGUYEN P, Yokoda RT, Hossain Q, Bederson JB, et al
    Solitary fibrous tumor-meningioma collision tumor with 18 years of follow-up.
    J Neuropathol Exp Neurol. 2025 Apr 11:nlaf037. doi: 10.1093.
    PubMed    
    
    
    February 2025
28. MORENO-TORRES B, Manzano-Benito I, Cantero D, Romo A, et al
    Integrating molecular analyses with the 2021 WHO classification of adult pilocytic astrocytomas.
    J Neuropathol Exp Neurol. 2025;84:255-263.
    PubMed     Abstract available
    
    
    December 2024
29. CHEN A, Hart SL, Lannon M, Hawkins C, et al
    Meningiomas in Rubinstein-Taybi syndrome: A case report and comprehensive review.
    J Neuropathol Exp Neurol. 2024 Dec 31:nlae135. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. VIZCAINO MA, Giannini C, Vaubel RA, Nguyen AT, et al
    Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma.
    J Neuropathol Exp Neurol. 2024;83:1003-1009.
    PubMed     Abstract available
    
    
    November 2024
31. GUO Y, Li Y, Su P, Yan M, et al
    Tumor microtubes: A new potential therapeutic target for high-grade gliomas.
    J Neuropathol Exp Neurol. 2024 Nov 19:nlae119. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
32. SHEKARIAN T, Ritz MF, Hogan S, Martins TA, et al
    Multidimensional analysis of matched primary and recurrent glioblastoma identifies contributors to tumor recurrence influencing time to relapse.
    J Neuropathol Exp Neurol. 2024 Oct 18:nlae108. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. CECCHI R, Guptil D, Haslett N, Hristov A, et al
    Primary CNS histiocytic sarcoma: Two case reports highlighting a novel MIGA2::BRAF gene fusion and genome-wide DNA methylation profiling results.
    J Neuropathol Exp Neurol. 2024;83:882-886.
    PubMed    
    
    
    September 2024
34. OHARA K, Al Assaad M, McNulty SN, Alnajar H, et al
    Detection of rare and novel gene fusions in patients with diffuse glioma: An institutional retrospective study.
    J Neuropathol Exp Neurol. 2024 Sep 28:nlae105. doi: 10.1093.
    PubMed    
    
    
    
35. REIMANN RR, Gramatzki D, Bink A, Hench J, et al
    Long survival in a patient with fumarate hydratase mutation-associated glioma.
    J Neuropathol Exp Neurol. 2024 Sep 16:nlae100. doi: 10.1093.
    PubMed    
    
    
    
36. KLEINSCHMIDT-DEMASTERS BK
    Mixed pituitary adenoma/pituitary neuroendocrine tumor-gangliocytoma: Immunohistochemical insights.
    J Neuropathol Exp Neurol. 2024;83:708-721.
    PubMed     Abstract available
    
    
    
37. FENG Y, Wong PJC, Fu M, Kong Y, et al
    The comprehensive morphological and molecular characteristics of lipoastrocytoma: A case report.
    J Neuropathol Exp Neurol. 2024;83:785-790.
    PubMed    
    
    
    August 2024
38. WANG C, Han H, Cheng F, Wang H, et al
    Clinical significance and potential mechanism of AEBP1 in glioblastoma.
    J Neuropathol Exp Neurol. 2024 Aug 27:nlae091. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. TIAN S, Xie G, Zhang H, Zuo F, et al
    A heritable form of SMARCE1-related meningiomas with clinical implications.
    J Neuropathol Exp Neurol. 2024 Aug 19:nlae080. doi: 10.1093.
    PubMed    
    
    
    
40. MORRIS M, Ararat K, Cutshall H, Gokden M, et al
    SMARCA4-deficient central nervous system metastases: A case series and systematic review.
    J Neuropathol Exp Neurol. 2024;83:638-654.
    PubMed     Abstract available
    
    
    
41. ABOUBAKR O, Senova S, Kauv P, Castel D, et al
    A non-midline unclassified glioneuronal tumor with H3K27M mutation enlarging the spectrum of CNS tumors H3K27ME3-altered.
    J Neuropathol Exp Neurol. 2024;83:701-705.
    PubMed    
    
    
    July 2024
42. TANAKA Y, Natsumeda M, Ohashi M, Saito R, et al
    Primary spinal cord gliomas: Pathologic features associated with prognosis.
    J Neuropathol Exp Neurol. 2024 Jul 29:nlae084. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. ALTURKUSTANI M, Walker AD, Castaneda EA, Cotter JA, et al
    Utility of OLIG2 immunostaining in pediatric brain tumors with embryonal morphology.
    J Neuropathol Exp Neurol. 2024 Jul 27:nlae082. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. KANATHANAVANICH M, Koga S, Stone SL, Roth J, et al
    CTDSP2::GLI1 fusion in glioblastoma: A diagnostic challenge through tumor heterogeneity.
    J Neuropathol Exp Neurol. 2024 Jul 9:nlae073. doi: 10.1093.
    PubMed    
    
    
    
45. LE MK, Tran NQV, Nguyen PT, Nguyen TA, et al
    Comprehensive analysis of distinct circadian clock subtypes of adult diffuse glioma and their associations with clinicopathological, genetic, and epigenetic profiles.
    J Neuropathol Exp Neurol. 2024 Jul 4:nlae055. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. FENG K, Ye G, Wang H, Li S, et al
    Research on the mechanism of TWSG1 in the malignant progression of glioma cells and tumor-associated macrophage infiltration.
    J Neuropathol Exp Neurol. 2024 Jul 1:nlae067. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
47. KISELJAK-VASSILIADES K, Lipe K, Turin CG, Fishbein L, et al
    E-cadherin expression and gene expression profiles in corticotroph pituitary neuroendocrine tumor subtypes.
    J Neuropathol Exp Neurol. 2024;83:586-595.
    PubMed     Abstract available
    
    
    
48. PARKER M, Kazemi F, Krishnakumar A, Horowitz MA, et al
    Availability and utilization of molecular testing for primary central nervous system tumors among US hospitals.
    J Neuropathol Exp Neurol. 2024;83:579-585.
    PubMed     Abstract available
    
    
    
49. ZSCHERNACK V, Thomas C, Schaub C, Kristiansen G, et al
    FH-mutant glioma displaying the epigenetic signature of IDH-mutant astrocytomas.
    J Neuropathol Exp Neurol. 2024 Jun 14:nlae064. doi: 10.1093.
    PubMed    
    
    
    
50. LORETO PALACIO P, Pan X, Jones D, Otero JJ, et al
    Exploring a distinct FGFR2::DLG5 rearrangement in a low-grade neuroepithelial tumor: A case report and mini-review of protein fusions in brain tumors.
    J Neuropathol Exp Neurol. 2024 Jun 4:nlae040. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
51. SHIBAHARA I, Nakashima T, Toyoda M, Inukai M, et al
    Evolving driver mutations in adult-onset SHH-medulloblastoma originated from radiological cerebellar abnormality.
    J Neuropathol Exp Neurol. 2024 May 29:nlae051. doi: 10.1093.
    PubMed    
    
    
    
52. VIZCAINO MA, Giannini C, Lalich D, Nael A, et al
    Ganglioglioma with anaplastic/high-grade transformation: Histopathologic, molecular, and epigenetic characterization of 3 cases.
    J Neuropathol Exp Neurol. 2024;83:416-424.
    PubMed     Abstract available
    
    
    April 2024
53. MACRAE CB, Grieco KC, Solomon IH
    Diagnostic yield of postmortem brain examination following premortem brain biopsy for neoplastic and nonneoplastic disease.
    J Neuropathol Exp Neurol. 2024;83:331-337.
    PubMed     Abstract available
    
    
    
54. WILCOCK DM, Goold E, Zuromski LM, Davidson C, et al
    EGFR/CEP7 high polysomy is separate and distinct from EGFR amplification in glioblastoma as determined by fluorescence in situ hybridization.
    J Neuropathol Exp Neurol. 2024 Apr 11:nlae028. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
55. KALTER JA, Yang RA, Toland A, Milla S, et al
    IDH-mutant astrocytoma arising from a demyelinating plaque in a child with X-linked adrenoleukodystrophy.
    J Neuropathol Exp Neurol. 2024;83:289-292.
    PubMed    
    
    
    
56. NEWMAN J, Leelatian N, Liang J
    Characterization of pediatric non-hematopoietic tumor metastases to the central nervous system: A single institution review.
    J Neuropathol Exp Neurol. 2024;83:268-275.
    PubMed     Abstract available
    
    
    
57. DONEV K, Sundararajan V, Johnson D, Balan J, et al
    Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    J Neuropathol Exp Neurol. 2024 Mar 6:nlae018. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
58. QI P, Yao QL, Lao IW, Ren M, et al
    A custom next-generation sequencing panel for 1p/19q codeletion and mutational analysis in gliomas.
    J Neuropathol Exp Neurol. 2024 Feb 26:nlae011. doi: 10.1093.
    PubMed     Abstract available
    
    
    
59. KRAUSE KA, Woods JK, Golby AJ, Lee EQ, et al
    Progestin-associated meningiomatosis with unusual schwannoma-like morphology.
    J Neuropathol Exp Neurol. 2024 Feb 1:nlae008. doi: 10.1093.
    PubMed    
    
    
    January 2024
60. XI S, Huang Q, Zeng J
    A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2024;83:125-130.
    PubMed     Abstract available
    
    
    
61. FENG Y, Xu H, Hu X, Zhang J, et al
    Heterogenous driving genetic events contribute to the dissemination of choroid plexus papilloma.
    J Neuropathol Exp Neurol. 2024;83:131-135.
    PubMed    
    
    
    
62. MARIET C, Grill J, Ajlil Y, Castel D, et al
    "Hemispheric pilocytic astrocytoma" revisited: A comprehensive clinicopathological and molecular series emphasizing their overlap with other glioneuronal tumors.
    J Neuropathol Exp Neurol. 2024;83:115-124.
    PubMed     Abstract available
    
    
    
63. ABOUBAKR O, Metais A, Doz F, Saffroy R, et al
    LEF-1 immunohistochemistry, a better diagnostic biomarker than beta-catenin for medulloblastoma, WNT-activated subtyping.
    J Neuropathol Exp Neurol. 2024 Jan 17:nlad104. doi: 10.1093.
    PubMed    
    
    
    
64. GUBBIOTTI MA, Weinberg JS, Weathers SP, Dasgupta P, et al
    An incidental finding of a high-grade glioma with pleomorphic and pseudopapillary features (HPAP) with PBRM1 mutation.
    J Neuropathol Exp Neurol. 2024 Jan 2:nlad114. doi: 10.1093.
    PubMed    
    
    
    December 2023
65. ROBINSON LJ, Goold E, Potter S, Quigley EP, et al
    A pleomorphic xanthoastrocytoma highlighting the morphological heterogeneity of this uncommon tumor.
    J Neuropathol Exp Neurol. 2023;83:61-64.
    PubMed    
    
    
    
66. GUNDOGDU F, Babaoglu B, Soylemezoglu F
    Reliability assessment of methylthioadenosine phosphorylase immunohistochemistry as a surrogate biomarker for CDKN2A homozygous deletion in adult-type IDH-mutant diffuse gliomas.
    J Neuropathol Exp Neurol. 2023 Dec 18:nlad109. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
67. GESTRICH C, Grieco K, Lidov HG, Baird LC, et al
    H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications.
    J Neuropathol Exp Neurol. 2023 Nov 30:nlad103. doi: 10.1093.
    PubMed     Abstract available
    
    
    
68. HUA Y, Youens KE, Castro E, Wang D, et al
    Autopsy findings in a 6-month-old infant with rhabdoid tumor predisposition syndrome 1: Case report with literature review.
    J Neuropathol Exp Neurol. 2023;82:1040-1043.
    PubMed    
    
    
    
69. WHITE B, Filo J, Orrego-Gonzalez E, Schwartz SN, et al
    Synchronous contralateral low-grade oligodendroglioma and high-grade IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2023;82:1048-1050.
    PubMed    
    
    
    
70. NUECHTERLEIN N, Shelbourn A, Cimino PJ
    Whole gain of chromosome 19, not co-gain of chromosomes 19 and 20, characterizes a class of glioblastomas with more favorable outcomes.
    J Neuropathol Exp Neurol. 2023 Nov 14:nlad092. doi: 10.1093.
    PubMed    
    
    
    
71. BLUM N, Mirian C, Maier AD, Mathiesen TI, et al
    Translocator protein (TSPO) expression in neoplastic cells and tumor-associated macrophages in meningiomas.
    J Neuropathol Exp Neurol. 2023 Nov 11:nlad093. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2023
72. NAZEM A, Lavezo J, Abdullaev Z, Aldape K, et al
    Diffuse hemispheric glioma with H3-3B G34R mutation: Expanding the spectrum of histone H3 genes in diffuse hemispheric glioma, H3 G34-mutant.
    J Neuropathol Exp Neurol. 2023 Oct 25:nlad089. doi: 10.1093.
    PubMed    
    
    
    
73. ABOUBAKR O, Metais A, Hasty L, Saffroy R, et al
    Brainstem oligodendroglioma, IDH-mutant, and 1P/19Q-codeleted: A potential diagnostic pitfall.
    J Neuropathol Exp Neurol. 2023;82:958-962.
    PubMed    
    
    
    
74. CAO C, Zhang L, Sorensen MD, Reifenberger G, et al
    D-2-hydroxyglutarate regulates human brain vascular endothelial cell proliferation and barrier function.
    J Neuropathol Exp Neurol. 2023;82:921-933.
    PubMed     Abstract available
    
    
    
75. SHELBOURN A, Nuechterlein N, Parada CA, Eaton J, et al
    Validating MCM2 as a clinically relevant surrogate immunohistochemical marker for an aggressive meningioma molecular subtype.
    J Neuropathol Exp Neurol. 2023 Oct 13:nlad082. doi: 10.1093.
    PubMed    
    
    
    
76. KOLEILAT A, Kumar V, Al Hmada Y, Milosevic D, et al
    Concurrent TERT promoter C228T and C250T mutations in diffuse gliomas: Rare occurrence of intratumoral heterogeneity.
    J Neuropathol Exp Neurol. 2023 Oct 9:nlad081. doi: 10.1093.
    PubMed    
    
    
    September 2023
77. XU E, Stone SL, Zhong Y, Golenberg N, et al
    A novel ARIH1::BRAF fusion in a glioma.
    J Neuropathol Exp Neurol. 2023 Sep 23:nlad074. doi: 10.1093.
    PubMed    
    
    
    
78. ZHANG Y, Huang H, Liu P, Xie Y, et al
    NFYB increases chemosensitivity in glioblastoma by promoting HDAC5-mediated transcriptional inhibition of SHMT2.
    J Neuropathol Exp Neurol. 2023 Sep 23:nlad073. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. YOKODA RT, Cobb WS, Yong RL, Crary JF, et al
    CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.
    J Neuropathol Exp Neurol. 2023;82:845-852.
    PubMed     Abstract available
    
    
    June 2023
80. GUBBIOTTI MA, Madsen PJ, Tucker AM, Abdullaev Z, et al
    ZFTA-fused supratentorial ependymoma with a novel fusion partner, DUX4.
    J Neuropathol Exp Neurol. 2023;82:668-671.
    PubMed    
    
    
    
81. MAIER AD, Christiansen SN, Haslund-Vinding J, Krogager ME, et al
    DNA methylation profile of human dura and leptomeninges.
    J Neuropathol Exp Neurol. 2023;82:641-649.
    PubMed     Abstract available
    
    
    
82. FUKUOKA K, Nakazawa A, Hirato J, Nobusawa S, et al
    An infantile pineal embryonal tumor showing pathological features of a CNS ganglioneuroblastoma and the methylation profiling of an atypical teratoid/rhabdoid tumor and SMARCA4 mutation.
    J Neuropathol Exp Neurol. 2023;82:664-667.
    PubMed    
    
    
    
83. BROGGI G, Barresi V
    Assessment of CDKN2A/B homozygous deletion in gliomas: To FISH or not to FISH?
    J Neuropathol Exp Neurol. 2023 Jun 12:nlad045. doi: 10.1093.
    PubMed    
    
    
    May 2023
84. LE MK, Vuong HG, Nguyen TTT, Kondo T, et al
    NAA10 overexpression dictates distinct epigenetic, genetic, and clinicopathological characteristics in adult gliomas.
    J Neuropathol Exp Neurol. 2023 May 30:nlad037. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. LIU X, Zhao J, Wu Q, Wang L, et al
    ANKRD22 promotes glioma proliferation, migration, invasion, and epithelial-mesenchymal transition by upregulating E2F1-mediated MELK expression.
    J Neuropathol Exp Neurol. 2023 May 10:nlad034. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2023
86. GUBBIOTTI MA, Dhillon KS, Harris J, Kothari S, et al
    An unusual case of metastatic diffuse midline glioma in an adult.
    J Neuropathol Exp Neurol. 2023 Apr 19:nlad032. doi: 10.1093.
    PubMed    
    
    
    
87. YANG X, Ye Z, Zhang M, Ouyang Y, et al
    Tissue clearing to examine glioma complexity in 3 dimensions.
    J Neuropathol Exp Neurol. 2023 Apr 6:nlad024. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2023
88. PERSONS JE, Eschbacher KL
    A case of dedifferentiated meningeal solitary fibrous tumor.
    J Neuropathol Exp Neurol. 2023;82:367-369.
    PubMed    
    
    
    
89. CONG H, Guo X, Fan B, Liu Y, et al
    Dimethylation of histone H3 lysine 36 (H3K36me2) as a potential biomarker for glioma diagnosis, grading, and prognosis.
    J Neuropathol Exp Neurol. 2023 Mar 15:nlad016. doi: 10.1093.
    PubMed     Abstract available
    
    
    
90. BRANDEL MG, Goodwill VS, Park A, Snyder V, et al
    Sudden unexpected death from hydrocephalus due to cerebellopontine angle meningioma.
    J Neuropathol Exp Neurol. 2023 Mar 2:nlad014. doi: 10.1093.
    PubMed    
    
    
    February 2023
91. GUBBIOTTI MA, Santi M, Storm PB, Li M, et al
    First-time identification of a KIF5B-NTRK2 fusion in extraventricular neurocytoma.
    J Neuropathol Exp Neurol. 2023;82:272-275.
    PubMed    
    
    
    
92. KLEINSCHMIDT-DEMASTERS BK, Ormond DR
    Leptomeningeal metastases and dural spread in adult high-grade astrocytomas.
    J Neuropathol Exp Neurol. 2023;82:194-201.
    PubMed     Abstract available
    
    
    
93. KANG MK, Ahn SJ, Ha J, Park SH, et al
    Natural killer T-cell primary CNS lymphoma presenting as lymphomatosis cerebri: a case report and literature review.
    J Neuropathol Exp Neurol. 2023;82:261-266.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.